Big Pharma (L)Earnings Season Q2'23: J&J, Novartis, Biogen, Roche

Teasing out key learnings from some Big Pharma Q2'23 earnings calls and what impact these may have on these companies, potential partners, and competitors

I’m testing out a new series, cheekily named “Big Pharma (L)Earnings”. Every quarter, the eyes of our sector are glued to earnings calls for the biggest companies in our space. There are so many sell-side analysts and internal competitive intelligence colleagues of yours who can do super detailed full-scale write ups of these calls. Rather than provide a detailed recap of every single Big Pharma earnings call, I’m going to tease out the nuggets of information I found most interesting from a selection of these calls and why these new insights could be meaningful to the company’s strategy and impact the industry in the future. I hope this series serves as a quick and easy way for you to gain a better understanding of the strategies driving the largest players in BioPharma and perhaps prompt you to think differently about your own company’s strategy. Let's get into it…

UPDATED 7/28: Included some insights regarding Biogen's acquisition of Reata